# Special Issue

# Experimental Models and Novel Therapies for Difficult-to-Treat Biofilm-Associated Infections

## Message from the Guest Editors

This Special Issue of *Antibiotics* will focus on two critical fronts in this battle: **experimental models** and **novel therapies**. Robust, physiologically relevant models (spanning sophisticated *in vitro* systems, ex vivo tissue models, and advanced *in vivo* infections) are essential for accurately mimicking the complex biofilm microenvironment and reliably evaluating new interventions. Concurrently, we urgently need to explore and validate groundbreaking therapeutic avenues. This includes, but is not limited to, anti-biofilm agents targeting matrix disruption or quorum sensing, biofilm-penetrating delivery systems, combination therapies, bacteriophages, antimicrobial peptides, and immunomodulatory approaches

## Guest Editors


Dr. Peng Gao

Applied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China

Dr. Xuan Li

Applied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China


## Deadline for manuscript submissions

closed (15 February 2026)


# Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/250082

*Antibiotics*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

# Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

# About the Journal

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

## Author Benefits

**Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )

MDPI